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Abstract 
Aims: Pulmonary arterial hypertension[1] is a proliferative disorder associated with enhanced 
proliferation and suppressed apoptosis of pulmonary artery smooth muscle cells (PASMCs). 
Reactive oxygen species (ROS) is implicated in the development of PAH and regulates the vascular 
tone and functions. However, which cellular signaling mechanisms are triggered by ROS in PAH is 
still unknown. Hence, here we wished to characterize the signaling mechanisms triggered by ROS. 
Methods and Results: By western blots, we showed that increased intracellular ROS caused 
inhibition of the glycolytic pyruvate kinase M2 (PKM2) activity through promoting the 
phosphorylation of PKM2. Monocrotaline (MCT)-induced rats developed severe PAH and right 
ventricular hypertrophy, with a significant increase in the P-PKM2 and decrease in pyruvate kinase 
activity which could be attenuated with the treatments of PKM2 activators, FBP and L-serine. The 
antioxidant NAC, apocynin and MnTBAP had the similar protective effects in the development of 
PAH. In vitro assays confirmed that inhibition of PKM2 activity could modulate the flux of 
glycolytic intermediates in support of cell proliferation through the increased pentose phosphate 
pathway (PPP). Increased ROS and decreased PKM2 activity also promoted the Cav1.2 expression 
and intracellular calcium. 
Conclusion: Our data provide new evidence that PKM2 makes a critical regulatory contribution to 
the PAHs for the first time. Decreased pyruvate kinase M2 activity confers additional advantages to 
rat PASMCs by allowing them to sustain anti-oxidant responses and thereby support cell survival in 
PAH. It may become a novel treatment strategy in PAH by using of PKM2 activators. 
 
Key words: ROS; PKM2; activators; pulmonary arterial hypertension. 
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1. Introduction 
Pulmonary arterial hypertension[1] is a severe disease caused by increased pulmonary vascular 
resistance (PVR) and pulmonary pressure[2]. PAH is associated with structural alterations of the 
pulmonary vessels [3] and characterized by abnormal pulmonary vasoconstriction and structural 
remodeling of the small pulmonary arteries. Pulmonary artery smooth muscle cells (PASMCs) 
undergo suppressed apoptosis, enhanced proliferation and migration in the pathogenesis of PAH 
[4]. Such alterations can be caused and exaggerated by reactive oxygen species (ROS) [5].  
ROS is critical to regulate vascular tone and functions [6]. In the lung, ROS is implicated in acute 
hypoxic vasoconstriction [7]. Nox-derived ROS is acutely activated in the pulmonary hypertension 
[8]. TGF-ß1 promotes HPASMC proliferation through a signaling pathway involving NOX4 
induction [9]. Nox1, but not Nox4 is responsible for pathophysiological proliferation and migration 
of PASMCs in MCT-induced PAH via increased ROS [10]. However, mechanisms underlining 
cellular signal pathways triggered by ROS remain unclear. 
The aerobic glycolysis involves conversion of glucose to lactate and the generation of ATP. 
Pyruvate kinase catalyzes the final step in glycolysis by transferring the phosphate from 
phosphoenolpyruvate (PEP) to ADP, thereby generating pyruvate and ATP [11]. The M2 isoform of 
pyruvate kinase (PKM2) is preferentially expressed in cancer [12] and is a central point of regulator 
in cancer metabolism [13]. PKM2 promotes the Warburg effect and tumorigenesis [14]. PKM2 is a 
PHD3-stimulated coactivator for hypoxia-inducible factor 1 in cancer [15]. Pyruvate kinase M2 
promotes de novo serine synthesis to sustain mTORC1 activity and cancer cell proliferation [16]. 
PKM2 could also regulate ß-catenin transactivation, cell proliferation and tumorigenesis in the 
activation of EGFR [17]. What’s more, PKM2 may confer an additional advantage to cancer cells 
by allowing them to withstand oxidative stress [18].  
It is well recognized that PASMCs proceed fundamental similarities with cancer cells in the 
pathogenesis of PAH. It is therefore important to know how PKM2 contributes to the development 
of PAH. In this paper, we investigated the roles of PKM2 in the pathogenesis of PAH and found 
that PKM2 activity decreased in response to the increased oxidative stress in the PAH, suggesting 
that PKM2 plays a key role in the PAH and also PKM2 activators may serve a novel treatment 
strategy in PAH.  
 
 
 
2. Methods 
2.1 Animals 
Animal experiments conformed to the Guide for the Institutional Animal Care and Use Committee 
(IACUC) and was approved by the Ethics Review Board for Animal Studies of Institute of 
Molecular Medicine (IMM), Peking University (Permit Number: IMM-GuYC-1). Adult male 
Sprague Dawley rats (250g) were purchased from Vital River (Beijing, China). Euthanasia was 
achieved by isoflurane inhalational anaesthesia (1.5%) and concurrent anaesthetic overdose as 
approved by the respective University IACUCs. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
4 
2.2 MCT treatment  
Monocrotaline(MCT, Sigma) was administered as a single subcutaneous injection in a dose of 60 
mg/kg
 
body mass. Control rats received an equal volume of isotonic saline. Rats were sacrificed 28 
days after MCT injection. 
2.3 Measurement of right ventricle hypertrophy 
Hearts were perfused with 0.9% saline and followed by constant-pressure infusion of saline for 
30 min with needle inserted into the left ventricle and a small hole in the right atrium, resulting in 
removal of residual blood. Using a dissecting microscope, the atria/valves and extraneous vascular 
material were removed from the heart. The free wall of the RV was dissected from the left ventricle 
(LV) and septum (S) and both portions were quickly blotted dry. A weight ratio of RV/(LV+S) was 
calculated to determine right ventricular hypertrophy. 
 
2.4 Isolation of pulmonary arterial smooth muscle cells 
Rats were anesthetized and the lung vasculature was flushed via the pulmonary artery with 0.9% 
NaCl in order to remove the blood. PASMCs were derived from pulmonary arterioles using the 
method as previously described [19]. The purity and identity of PASMCs were confirmed using 
specific α-smooth muscle actin (α-SMA) antibodies, a protein marker for PASMCs. 
2.5 Histology  
The lung tissues were obtained from anesthetized rats, sliced into tissue blocks, and immersed in 
4% paraformaldehyde for overnight fixation. Fixed tissues were then dehydrated, cleared, and 
embedded in paraffin wax. The tissues were cut into 5 μm thick sections and stained with 
hematoxylin and eosin (H&E). Results are expressed as the wall thickness. The sections were 
viewed with an Eclipse 600 Nikon microscope and photographed with a digital camera. 
Morphometric analysis was analyzed with Image J software. 
2.6 Immunoblotting 
Cells and lung tissues were lysed ice-cold RIPA lysis buffer (Solarbio) including PMSF and 
proteinase inhibitor cocktail (Roche). Samples were centrifuged for 15min at 12,000g at 4°C and 
the supernatants were harvested. About 60 ug of each protein sample were loaded and separated on 
10% Bis-Tris Gel followed by transferring to 0.45 mm PVDF membrane. The membranes were 
then blocked with 5% non-fat dry milk, probed with appropriate primary antibodies, followed 
incubation by HRP-conjugated secondary antibodies at a dilution of 1: 5000. The following 
antibodies were used: rabbit anti-Phospho-PKM2 (Tyr105) (Cell Signaling, #3827), rabbit anti-
PKM2 (Cell Signaling, #3198), mouse anti-ß-actin (Beijing TDY Biotech LTD, #M009), HRP-
conjugated secondary mouse (Beijing TDY Biotech LTD, #E009) and rabbit antibodies (Beijing 
TDY Biotech LTD, #E011). 
2.7 Quantitative RT-PCR  
Total RNA was extracted from lung tissues and RPASMCs. mRNA was reverse transcribed using 
random primers and cDNA synthesis Kit (TransGen Biotech). The resulting cDNAs were mixed 
with the SYBR PCR master mix (TransGen Biotech) and run on the Step-One Plus Applied 
Biosystems Real-time PCR machine. One cycle of denaturing step (30 sec at 94ºC) was applied, 
followed by 40 cycles of amplification (5 sec at 94ºC and 30sec at 60ºC), with fluorescence 
measured during the extension. 18s was as the house keeping gene to normalize the gene 
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expression. Calculations were performed by a comparative method (2
-∆∆Ct
). Primers used in this 
study are listed below. 
GPX1: F: 5’-GCTCACCCGCTCTTTACC-3’; R: 5’-AACACCGTCTGGACCTACC-3’ 
PHGDH: F: 5’-GGGGAGGAAATCGCAGTC-3’; R: 5’-TAGCGTTCACCAAGTTCACATC-3’ 
PSAT1: F: 5’-GGGGTGACGGTAGTGATT-3’; R: 5’-CATCCTGCTTCTATTCTGG-3’ 
PSPH: F: 5’-GTTGCCTTTCAAAGATGCG-3’; R: 5’-CGTGCTCCACAATACTCCTAA-3’ 
18s: F: 5’-CGAACGTCTGCCCTATCAACT-3’; R: 5’ CAGACTTGCCCTCCAATGGATCCTCGTT-3’. 
 
2.8 PKM2 activity assay 
 
PK activity was measured in an LDH-coupled enzymatic assay as described previously
[20]
, either 
from cell extracts or rat serum.  
2.9 Glucose, lactate and GSH/GSSG measurement 
Cell media was collected from wells; spun down at high speed to remove any cell debris, 
deproteinized using TCA, pH was adjusted between 7.0-7.5 and then glucose uptake was analyzed 
using glucose assay kit (Sigma, #GAGO-20), according to manufacturer’s protocols. Lactate was 
analysed using kit (BioAssay, ECLC-048) as per manufacturer’s instructions. GSH/GSSH was 
analysed using kit (Beyotime, #S0055) according to manufacturer’s protocols. 
 
2.10 Proliferation assays  
For determination of proliferation, MTT assay was used as reported previously. Briefly, RPASMCs 
were seeded at a density of 1,000 per well into 96-well cell culture plates and allowed them to 
adhere for 24h. After different treatments, 20 ml of MTT was added to each well for 3h incubation. 
Subsequently, cells were dissolved by 150 mL of DMSO, mixed and measured the absorbance (A) 
by Multiskan (Thermo) at 540nm. The relative proliferation rate was calculated by the absorbance 
ratio of the drug-treated group to the control group.  
2.11 Measurements of Intracellular reactive oxygen species 
Intracellular ROS was quantified by a laser confocal microscope using the fluorescent probe, 2′,7′-
dichlorodihydrofluorescein diacetate (DCFH-DA). RPASMCs were incubated in phenol red-free 
media supplemented with 10 μM DCFH-DA in dark for 20 min at 37°C. They were then washed 
twice with PBS and immediately observed. 
2.12 Calcium imaging  
Calcium imaging was performed using Fura-8
TM
 
(AAT Bioquest) according to previous description. 
Fluorescence images of the cells were recorded and analyzed with a video image analysis system.  
2.13 Statistical Analyses 
The Student’s t-test was used for the statistical analysis of all the independent experiments. Data are 
expressed as average ± SEM of at least three independent experiments. A p-value of <0.05 was 
considered statistically significant. 
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3. Results 
3.1 Isolated pulmonary arterial smooth muscle cells were sensitive to the glycolysis inhibitor. 
PASMCs are a major site of vascular remodeling underlying pulmonary hypertension [21]. To 
assess the key metabolic way of rat PASMCs (RPASMCs), RPASMCs were isolated from SD rats 
and stained for α-SMA (Data not shown). Then isolated RPASMCs were treated with different 
concentration of 2-DG and oligomycin. 2-DG is an inhibitor of glycolysis and oligomycin is the 
inhibitor of mitochondrial oxidative phosphorylation. As a result, 2-DG obviously inhibited 
intracellular ATP production of RPASMCs in a dosage-dependent manner, while oligomycin had 
no effect (Fig.1A). The data suggested that glycolysis was the dominant metabolic way for 
RPASMCs. The key enzymes involved in the glycolysis might function in the development of 
PAH.  
3.2 P-PKM2 expression increased and pyruvate kinase activity decreased in the PAH. 
MCT injection led to pulmonary hypertension with an increase in right ventricular systolic pressure 
(RVSP) and a right heart hypertrophy as depicted by the increment in the ratio of the right 
ventricle/(left ventricle plus septum) (Data not shown). In the lung tissues from MCT-PAH rats, P-
PKM2 expression significantly increased compared with the healthy rats, but the total PKM2 
expression had no changes (Fig.1B). Additionally, in the isolated RPASMCs, hypoxia (1%O2) also 
induced increase of P-PKM2 (Fig.1C). Phosphorylation of PKM2 at Tyr105 remains a major 
observation known for reduction in PKM2 activity, playing an important role in the pooling of 
metabolites [22]. Consistently, the decrease in PKM2 activity corresponding with the increased 
phosphorylation of PKM2 was observed in the serum of MCT-treated rat and the cell lysates 
generated from hypoxia RPASMCs (Fig.1D&E). 
3.3 PKM2 activators could reverse the development of pulmonary hypertension induced by 
MCT in vivo. 
To assess definitively the function of PKM2 in regulating the development of PAH, PKM2 
activators (L-serine and FBP) were used in the MCT-PAH rats. They were intragastric 
administration one week after rats developing PAH. L-serine and FBP both could rescue the weight 
of MCT-induced rats (Fig.2A) and the index of right ventricular hypertrophy (Fig.2B). Lymphoid 
follicles were induced in the lung on infection or chronic inflammation lymphoid follicles in 
chronic lung diseases [23] and FBP could attenuate the number of lymphoid follicles, while L-
serine had no obvious effects (Fig.2C). Additionally, FBP and L-serine both contributed to the 
beneficial effects in attenuating pulmonary vascular remodeling in the PAH, including the widened 
alveolar interval and the decreased wall thickness of small arteries (Fig.2D). 
3.4 Increased intracellular ROS generation in PAH. 
DCFH-DA was used to test the intracellular ROS generation. RPASMCs treated in hypoxia or 
isolated from MCT-induced rats both had increased intracellular ROS levels (Fig.3A). The 
antioxidant NAC, NOX inhibitor apocynin and SOD mimetics MnTBAP which could abolish the 
intracellular ROS, inhibited the over-proliferation induced by hypoxia (Fig.3B). NAC, apocynin 
and MnTBAP also could decrease the phosphorylation of PKM2 (Fig.3C) and activated the 
pyruvate kinase activity (Fig.3D) induced by hypoxia. Concurrently, the lactate production 
increased in hypoxia by treatment with ROS inhibitors (Fig.3E). As expected in vivo PAH rats, 
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NAC could decrease the expression of P-PKM2 in the lung tissues of MCT-induced rats (Fig.3F) 
and attenuate MCT-induced the development of pulmonary hypertension and vascular remodeling. 
For example, NAC could reverse the rat weight (Fig.3G), the RV/(LV+S) (Fig.3H), number of 
lymph follicles (Fig.3I) and wall thickness (Fig.3J) in the MCT-PAH. 
3.5 Decreased glycolysis and serine synthesis, increased pentose phosphate pathway in the 
pulmonary hypertension.  
To determine the mechanism that decreased PKM2 activity could promote the development of 
PAH, we tested the glucose consumption and lactate production in the supernatant of RPASMCs 
and the MCT-induced rat serum. The glucose consumption had no changes (Fig.4A), but the lactate 
production significantly decreased (Fig.4B). As a response to oxidative stress, we expected changes 
in the regulation of the antioxidative capacity of the cells. The mRNA of the antioxidative enzyme 
catalase and glutathione peroxidase 1 (GPX1) decreased in the RPASMCs in hypoxia for 2h and 
increased for 24h (Fig.4C). Consistent with the mRNA expression of GPX1, the ratio of 
GSH/GSSG decreased in the RPASMCs in hypoxia for 2h and increased for 24h (Fig.4D) which 
means that pentose phosphate pathway may function in this process. Furthermore, there are three 
enzymes, 3-phospho-glycerate dehydrogenase (PHGDH), phosphoserine aminotransferase 1 
(PSAT1), and phosphoserine phosphatase (PSPH), which are required for the three-step conversion 
of the glycolytic intermediate 3-PG to serine [16]. In the lung tissues from MCT and hypoxia-
induced RPASMCs, mRNA expression of PHGDH, PSAT1 and PSPH all decreased (Fig.4E), 
suggesting the decrease of serine synthesis in the PAH. This implicated that decreased PKM2 
activity may favour biomass generation.  
 
3.6 Cav1.2 expression increased in the PAH and it was in the downstream of ROS and PKM2. 
Elevation of Ca
2+
 influx in PASMCs plays an important role in PAH. The microRNA-328 regulates 
hypoxic pulmonary hypertension by targeting at insulin growth factor 1 receptor and L-type 
calcium channel-alpha1C [24]. We found that under the stimulation of MCT-treatment as well as 
hypoxia exposure, Cav1.2 protein expression significantly increased in the lung tissues (Fig.5A 
&B). PKM2 activator and ROS inhibitors could reverse the increased expression of Cav1.2 induced 
by hypoxia in RPASMCs (Fig.5C&E). Moreover, calcium flux in RPASMCs could be inhibited 
when adding PKM2 activator and ROS inhibitors (Fig.5D&F). Taken together, Cav1.2 was thus in 
the downstream of ROS and PKM2. 
 
 
4. Discussion 
In the present study, we have demonstrated that intracellular oxidative stress increased in the 
RPASMCs from MCT and hypoxia-induced PAH rats. Increasing ROS led to the increased 
phosphorylation of PKM2 and decreased PKM2 activity. The emerging PKM2 inactivation 
triggered increased proliferation due to elevated pentose phosphate pathway, decreased glycolysis 
and serine synthesis. Furthermore, the inactivation of PKM2 also increased the expression of 
Cav1.2, which also could enhance the proliferation of RPASMCs and promote the hypoxia-induced 
vasoconstriction.  
Previous studies have confirmed increased oxidative stress in the RPASMCs in the PAH. 
Mitochondria and Nox are the master sources of altered ROS generation in PAH [25]. NADPH 
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oxidases recently have been proposed as possible pulmonary oxygen sensors for the acute response 
to hypoxic pulmonary vasoconstriction [26]. Reactive oxygen species (ROS) thus plays a major role 
in the vascular remodeling that occurs during chronic alveolar hypoxia [27]. However, cellular 
signaling mechanisms regulated by ROS are still unknown. In respect with the possible mechanism, 
we found that the isolated RPASMCs were sensitive to 2-DG, an inhibitor of glycolysis, suggesting 
the glycolysis may function in the development of PAH. Additionally, increased phosphorylation of 
PKM2 and decreased PKM2 activity in the PAH implicated that PKM2 is a key enzyme, which has 
been studied in various cancer cells [28]. Then we established MCT-PAH rat models and fed with 
PKM2 activators L-serine and FBP. Serine is an allosteric activator of KM2, promoting the shift 
of the less active dimeric form to an active tetrameric form [29]. Fructose-1,6-bisphosphate (FBP) 
is an endogenous activator of PKM2 [30]. Surprisingly, they both reversed the development of 
MCT-PAH. 
To determine whether PKM2 was triggered by ROS in vivo, we treated MCT-PAH rats with the 
antioxidant NAC. This difference in rat weight, RV/(LV+S), number of lymph follicles and wall 
thickness were alleviated when treated with NAC. This phenomenon shed the light on the benefit of 
reduced PKM activity is for RPASMCs in PAH. In cancer cells, it has been well-known that lower 
activity of PKM2 promotes the accumulation of upstream glycolytic intermediates, which are 
precursors for biosynthesis of nucleotides, amino acids, and lipids required for proliferation [31]. In 
addition, reduced pyruvate kinase activity in PKM2-expressing cells would lead to accumulation of 
3-PG, which could then be converted to serine [16]. The accumulation of glucose-6-phosphate 
shifts glucose flux through the pentose phosphate pathway (PPP) [18], resulting in decreased lactate 
production and serine synthesis in the PAH. However, pentose phosphate pathway was 
appropriately enhanced in order to sustain proliferation through the accumulation of GSH.  
Our results also identified Cav1.2 as a potential downstream target of PKM2. Many studies 
indicated that Cav1.2 is an essential regulator of PA construction [32]. In this study, we found that 
Cav1.2 expression increased in the PAH and it could be reversed in the treatment with NAC and L-
serine.  
 
In this paper, the right ventricular systolic pressure (RVSP) measurement and the metabolic 
analysis using analysis of 
13
C-labeled metabolites were lacking because of the limitation of 
instruments. 
  
In conclusion, our data provide new evidence that PKM2 plays a dominant role in the pathogensis 
of PAH. Decreased pyruvate kinase M2 confers additional advantages to RPASMCs by allowing 
them to sustain anti-oxidant responses and thereby support cell survival in PAH. It may become a 
novel treatment strategy in PAH by using of PKM2 activators. 
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Glossary 
PAH: Pulmonary arterial hypertension 
PKM2: pyruvate kinase M2 
PASMC: pulmonary artery smooth muscle cells 
ROS: reactive oxygen species 
MCT: Monocrotaline 
GPX1: glutathione peroxidase 1 
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Figure legends 
 
Figure 1. Increasing expression of P-PKM2 in the lung tissues from pulmonary hypertension rats.  
A. Effects of different concentration of 2-DG (n=8) and oligomycin (n=8; P=NS) on the 
intracellular ATP production in the cultured RPASMCs. 2-DG is an inhibitor of glycolysis and 
oligomycin is the inhibitor of oxidative phosphorylation. 
B. Western blot analysis of P-PKM2 and PKM2 expression in the lung tissues from MCT-induced 
PAH rats. Quantitative analysis was presented in the graph. Data were normalized to β-actin 
(n=5).  
C. Western blot analysis of P-PKM2 and PKM2 expression in RPASMCs treated in normoxia and 
hypoxia. Quantitative analysis was presented in the graph. Data were normalized to β-actin 
(n=3). 
D. Pyruvate kinase catalytic activity in the serum from the MCT rats and the healthy rats (n=5). 
E. Pyruvate kinase catalytic activity from normoxia and hypoxia-treated RPASMCs (n=5). Results 
represented mean ± SEM of n independent experiments. NS, not significant. **P<0.01, *P<0.05, 
1-way ANOVA. 
 
Figure 2. PKM2 activators attenuated MCT-induced the development of pulmonary hypertension 
and vascular remodeling. 
A. Rat weight was evaluated when treated with PKM2 activators, L-serine (315mg/kg) and FBP 
(460mg/kg) in MCT-induced PAH (n=6).  
B. Fulton index: RV/(LV+S). The right ventricle (RV) to left ventricle (LV) plus septum (S) ratio 
was quantified when treated with PKM2 activators, L-serine and FBP in MCT-induced PAH 
(n=6).  
C. Left: Representative micrographs of lymphoid follicles (LFs) located between pulmonary 
arteries and stained by hematoxylin and eosin; right: Lymphoid follicles were counted on the per 
entire lung slide when treated with L-serine and FBP in MCT-induced PAH (n=6). Scale bars, 
100um.  
D. Representative micrographs of pulmonary alveoli and the PA wall thickness on lung sections 
when treated with L-serine and FBP in MCT-induced PAH (n=6). Scale bars, 50um. Results 
represented mean ± SEM of n independent experiments. **P<0.01, *P<0.05, 1-way ANOVA.  
 
Figure 3. Increased intracellular ROS generation in PAH. 
A. ROS staining was performed using DCFH-DA in RPASMCs treated in hypoxia or isolated from 
MCT-induced PAH rats. Left: Representative images of ROS staining; right: Statistics of ROS 
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fluorescence intensity in per picture (n=8). Scale bars, 100um.  
B. Effects of antioxidants (NAC, apocynin and MnTBAP) on the over-proliferation of RPASMCs 
induced by hypoxia in vitro (n=10).  
C. Western blots analyzed the effects of ROS inhibitors on the expression of P-PKM2 in 
RPASMCs in hypoxia (n=3). Nor, normoxia; apoc, apocynin; Mn, MnTBAP. 
D. Pyruvate kinase catalytic activity from hypoxia-treated RPASMCs with the treatment of 
different ROS inhibitors (n=5). 
E. Effects of ROS inhibitors on the lactate production in the supernatant of RPASMCs (n=4). 
F. Effects of NAC on the expression of P-PKM2 and PKM2 in the lung tissues of the MCT-
induced PAH rats (n=5).  
G. Rat weight was evaluated in rats when treated with the antioxidant NAC in MCT-induced PAH 
rats (n=5).  
H. RV/(LV+S) was calculated in rats when treated with the antioxidant NAC in MCT-induced 
PAH rats (n=5).  
I. Effects of NAC on the number of lymph follicles in the lung tissues of MCT-induced PAH rats 
(n=5).  
J. Effects of NAC on the pulmonary alveoli and the PA wall thickness in MCT-induced PAH rats. 
Quantitative analysis is presented in the graph. Scale bars, 50um. Results represented mean ±
SEM of n independent experiments. **P<0.01, *P<0.05,1-way ANOVA. 
 
Figure 4. Decreased glycolysis and serine synthesis, increased pentose phosphate pathway in the 
pulmonary hypertension.  
A. The glucose consumption had no change in the supernatant of RPASMCs in hypoxia 
(n=3,P=NS) and in the MCT rat serum (n=5,P=NS) compared to controls.  
B. The production of lactate decreased in the supernatant of RPASMCs in hypoxia (n=4) and in the 
MCT rat serum (n=5) compared to controls.  
C. Quantitative PCR results. The mRNA expression of anti-oxidative enzyme GPX1 in the 
RPASMCs in hypoxia for 2 hours and 24 hours (n=3). 
D. The ratio of GSH/GSSG in the RPASMCs treated in hypoxia for 2 hours and 24 hours (n=3).   
E. The mRNA expression of key enzymes involved in serine synthesis, including PHGDH, PSAT1 
and PSPH from the lung tissues of MCT (n=5) and RPASMCs in hypoxia compared to control 
(n=4). Results represented mean ± SEM of n independent experiments. NS, not significant. 
**P<0.01, *P<0.05,1-way ANOVA. 
 
Figure 5.  Cav1.2 expression increased in the PAH and was inhibited by ROS inhibitors and PKM2 
activators. 
A. Western blot analysis of Cav1.2 expression in the lung tissues from MCT-induced PAH rats. 
Quantitative analysis was presented in the graph. Data were normalized to β-actin (n=4).  
B. Western blot analysis of Cav1.2 expression in the lung tissues from hypoxia-induced PAH rats. 
Quantitative analysis was presented in the graph. Data were normalized to β-actin (n=6). 
C. Effects of L-serine on the expression of Cav1.2 in RPASMCs treated in hypoxia. Data were 
normalized to β-actin (n=3). 
 Effects of PKM2 activators (L-serine and FBP) on intracellular calcium concentration in 
RPASMCs. RPASMCs were loaded with Furo-8 for 30 minutes, as described in ‘Materials and 
Methods’. Baseline [Ca2+]i was recorded, followed by sequential additions of 80 mM KCl at the 
150th picture (n=10). 
E. Effects of ROS inhibitors (NAC, apocynin and MnTBAP) on the expression of Cav1.2 in 
RPASMCs treated in hypoxia. Nor, normoxia; Apop, apocynin; Mn, MnTBAP. Data were 
normalized to β-actin (n=3). 
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F. Effects of ROS inhibitors (NAC, apocynin and MnTBAP) on intracellular calcium concentration 
in RPASMCs. Baseline [Ca
2+
]i was recorded, followed by sequential additions of 80 mM KCl at 
the 150th picture (n=10). Results represented mean ± SEM of n independent experiments. 
*P<0.05,1-way ANOVA. 
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Highlights: 
 Decreased pyruvate kinase M2 activity confers to the development of PAH. 
 ROS-PKM2-Cav1.2 axis functions in the PAH. 
 PKM2 activators may become a novel treatment strategy in PAH. 
